Holen Sie sich die Stockscreener-App
524.99
0.13%
-0.68
Vorhandelsmarkt:
525.00
0.010
+0.00%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$525.67
Offen:
$532.1
24-Stunden-Volumen:
302.71K
Relative Volume:
0.83
Marktkapitalisierung:
$12.04B
Einnahmen:
$958.40M
Nettoeinkommen (Verlust:
$-288.28M
KGV:
-40.81
EPS:
-12.8641
Netto-Cashflow:
$-193.02M
1W Leistung:
+2.56%
1M Leistung:
+18.02%
6M Leistung:
+20.11%
1J Leistung:
+62.88%
1-Tages-Spanne:
$518.80
$539.16
1-Wochen-Bereich:
$503.93
$539.16
52-Wochen-Spanne:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
524.99 | 11.92B | 958.40M | -288.28M | -193.02M | -12.86 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Grants Equity Awards to 20 New Employees - MyChesCo
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
What makes Madrigal Pharma (MDGL) one of the shorted biotech stocks to buy - MSN
Is Madrigal Pharmaceuticals (MDGL) Still Attractively Priced After Its 20% Monthly Surge? - Yahoo Finance
Why (MDGL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? - Sahm
Madrigal Pharmaceuticals Inc (HAM:YDO1) Stock Price, Trades & News - GuruFocus
Fed Watch: What is the dividend yield of Madrigal Pharmaceuticals Inc2026 Market Overview & Growth Oriented Trading Recommendations - baoquankhu1.vn
Dip Buying: Is Madrigal Pharmaceuticals Inc stock good for income investors2026 Intraday Action & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Breakouts Watch: Can Madrigal Pharmaceuticals Inc weather a recession2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
Madrigal Pharmaceuticals Grants Inducement Awards to New Employees - National Today
Madrigal Pharmaceuticals, Inc. (MDGL) stock price, news, quote and history - Yahoo Finance UK
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rheos Capital Works Inc. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Winners Losers: Is now the right time to enter Madrigal Pharmaceuticals IncQuarterly Earnings Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals (MDGL) - MSN
Capricorn Fund Managers Ltd Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN
MDGL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Toth Financial Advisory Corp Makes New $1.17 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL - marketbeat.com
Madrigal Pharmaceuticals Grants Equity Awards to New Employees Under 2025 Inducement Plan - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Madrigal Pharmaceuticals to Present at Morgan Stanley Global Health Care Conference - MSN
Madrigal grants equity awards to seven new employees - MSN
Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra - Sahm
Madrigal Soars 5.87% on Strong Analyst Momentum and Institutional Shifts—Where to Now? - bitget.com
Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
MDGL Technical Analysis | Trend, Signals & Chart Patterns | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill
Understanding Momentum Shifts in (MDGL) - Stock Traders Daily
Madrigal Pharmaceuticals grants equity awards to 20 new employees - MSN
Madrigal Pharmaceuticals (MDGL) surged on strong sales of its Rezdiffra drug - MSN
Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals stock dips after team presence at Liver Connect Conference sees doubled attendance - Traders Union
Madrigal Reports $212.8M in Q2 Rezdiffra Sales, Expands Global Pipeline and Secures $500M Financing - MSN
Loss Report: What are analysts price targets for Madrigal Pharmaceuticals Inc2026 Bull vs Bear & Technical Pattern Based Signals - baoquankhu1.vn
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug - Insider Monkey
Vanguard (MDGL) files amendment; reports 0 shares after Jan 12, 2026 realignment - Stock Titan
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains? - Yahoo Finance
Madrigal Pharmaceuticals gains amid renewed takeover speculation - MSN
Rezdiffra Shows Promise as Madrigal’s Liver Drug Garners Positive Results - StocksToTrade
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):